0001517681 false --06-30 0001517681 2022-07-06 2022-07-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549






Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): July 6, 2022



(Exact name of registrant as specified in its charter)


Delaware   000-54878   33-0662986

(State or other jurisdiction

of incorporation)



File Number)


(I.R.S. Employer

Identification No.)


302, 6 Butler Street

Camberwell, VIC, 3124 Australia

(Address of principal executive offices) (Zip Code)


+61-03- 9882-0780

(Registrant’s telephone number, including area code)



(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:


Title of each class   Trading Symbol(s)   Name of principal U.S. market on which traded
N/A   N/A   N/A


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐







Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.


On May 18, 2022, the board of directors of Propanc Biopharma, Inc. (the “Company”) approved and authorized, and the holders of a majority in interest of the Company’s voting capital stock (the “Voting Stockholders”) approved by written consent, in accordance with Section 228 of the Delaware General Corporation Law, for the Company to file a Certificate of Amendment to its Certificate of Incorporation (the “Certificate”) with the Secretary of State of the State of Delaware, which increased the Company’s authorized capital stock as described below. The Certificate was filed and became effective on July 6, 2022.


The Certificate increased the number of authorized shares of the Company’s common stock, par value $0.001 per share, from 1,000,000,000 to 3,000,000,000. The number of authorized shares of preferred stock remains at 1,500,005, such that the total number of shares of all classes and series the Company is authorized to issue is 4,001,500,005 shares.


Item 5.07 Submission of Matters to a Vote of Security Holders.


The information in Item 5.03 above regarding the approval of the Certificate by written consent of the Company’s Voting Stockholders is incorporated herein by reference.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits:


Exhibit No.   Description
3.1*   Certificate of Amendment to the Certificate of Incorporation, dated, July 6, 2022
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)


* Filed herewith







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  By: /s/ James Nathanielsz
  Name:  James Nathanielsz
Dated: July 11, 2022 Title:  Chief Executive Officer